Abbott Laboratories $ABT Shares Bought by Bank of Nova Scotia

Bank of Nova Scotia grew its position in Abbott Laboratories (NYSE:ABT) by 53.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 315,827 shares of the healthcare product maker’s stock after acquiring an additional 110,323 shares during the quarter. Bank of Nova Scotia’s holdings in Abbott Laboratories were worth $42,302,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Carr Financial Group Corp raised its position in Abbott Laboratories by 2.0% in the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after purchasing an additional 76 shares during the last quarter. Tortoise Investment Management LLC grew its position in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares during the last quarter. Gemmer Asset Management LLC increased its stake in Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after purchasing an additional 78 shares during the period. Global Financial Private Client LLC raised its holdings in shares of Abbott Laboratories by 3.3% in the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock valued at $331,000 after buying an additional 79 shares during the last quarter. Finally, Citizens & Northern Corp boosted its stake in shares of Abbott Laboratories by 0.4% during the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $107.99 on Monday. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The company has a 50-day moving average price of $114.58 and a 200 day moving average price of $123.80. The company has a market cap of $187.66 billion, a P/E ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Analyst Upgrades and Downgrades

ABT has been the topic of several recent research reports. Citigroup dropped their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Sanford C. Bernstein decreased their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Argus cut their price target on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Finally, Evercore decreased their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.